Key Points
• In the current review, authors examined the current milieu for DLBCL treatment including monoclonal antibodies, antibody–drug conjugates, bispecific antibodies and chimeric antigen receptor (CAR) T cells. Although the authors were encouraged by the gamut of new treatment options, they stressed this variety made it challenging for clinicians to pick out the timing and indications of these new immunotherapies.
• They noted that CAR-T cell therapy can be used as third-line therapy in patients to proffer durable response, with other agents available if autologous stem cell transplant (ASCT) or CAR-T cells fail. One agent discussed is tafasitamab (Monjuvi).
• “The CD19 monoclonal antibody tafasitamab has a demonstrable role in the r/r setting, but its utility is unclear in patients with high-risk disease including double- and triple-hit and primary refractory disease who were excluded from the study,” the authors wrote. “Despite this fact, the tafasitamab/lenalidomide combination can be considered in patients unfit for ASCT and CAR T cell therapy or in patients relapsed after these therapies with ongoing CD19 expression.”